Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 11 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride replenishes potassium stores; potassium is the major intracellular cation and is essential for nerve conduction, muscle contraction, and acid-base balance. Dextrose provides calories and sodium chloride supplies sodium and chloride ions to maintain electrolyte balance.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
IV infusion: 1 L contains 20 mEq K+, 50 g dextrose, and 77 mEq Na+ and Cl- each. Adjust rate based on potassium deficit and serum potassium. Typical adult rate: 10-20 mEq/hour via peripheral IV, not to exceed 40 mEq/hour or 200 mEq/day.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: not applicable (homeostatic regulation); dextrose and sodium: endogenous, no elimination half-life. For exogenous potassium, distribution half-life ~1-1.5 h.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal excretion: >90% of potassium is eliminated via kidneys; <10% fecal. Dextrose and sodium are primarily metabolized or renally excreted.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."